Category: Mergers & AcquisitionsSyndicate content

Allergan cuts 1,500 jobs, faces SEC complaint

July 21, 2014 by Arezu Sarvestani

Botox-maker Allergan announces restructuring measures that will cut 13% of its global workforce as the company sinks deeper into a months-long battle against activist investors and attempts at a takeover.

Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan's earnings.

A countdown to failure for Valeant's hostile $53B Allergan takeover

July 18, 2014 by Arezu Sarvestani

Activist investor Bill Ackman urges shareholders to take action before time runs out on Valeant Pharmaceuticals' hostile $53 billion bid to acquire Allergan.

A countdown to failure for Valeant's hostile $53B Allergan takeover

Abbott CEO defends inversions amid corporate exodus furor

July 18, 2014 by Arezu Sarvestani

Abbott chairman & CEO Miles White chides critics of corporate inversions as Capitol Hill mulls legislation to strip tax benefits for companies that shift their headquarters overseas.

Abbott CEO defends inversions amid corporate exodus furor

Siemens sells clinical microbiology biz to Beckman Coulter

July 17, 2014 by Arezu Sarvestani

Beckman Coulter picks up Siemens Healthcare Diagnostics' clinical microbiology business in a closed-doors deal.

Siemens sells clinical microbiology biz to Beckman Coulter

Medtronic fights tax dodging rhetoric in Covidien merger

July 17, 2014 by Arezu Sarvestani

Medtronic ensures shareholders that the company remains beholden to (nearly) all U.S. corporate taxes as it shifts its headquarters overseas.

Medtronic fights tax evasion rhetoric in Covidien merger

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

July 16, 2014 by Arezu Sarvestani

Lawmakers aim to prohibit companies from shifting their headquarters overseas in order to evade U.S. taxes, a measure that would apply retroactively to deals such as Medtronic's $43 billion acquisition of Covidien.

Could Medtronic-Covidien deal get caught in anti-inversion legislation?

Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere

July 16, 2014 by Brad Perriello

Johnson & Johnson CEO Alex Gorsky says the healthcare giant is eyeing acquisitions to bolster its 'subscale' cardiovascular business and, possibly, other aspects of its medical device business.

YYmeta

The world's largest medical device operation is eyeing acquisitions to bolster its "subscale" cardiovascular business, particularly its electrophysiology business, Johnson & Johnson (NYSE:JNJ) chairman & CEO Alex Gorsky told analysts yesterday.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp